CRISPR Therapeutics: Beyond the Hype, A Foundational Investment in Gene Editing's Future
A CRISPR Conundrum: Intellia's Trial Halt Jolts the Biotech World
CRISPR/Vertex gene editing therapy approved in U.S. for beta thalassemia